A study about combination cancer treatments for people with acute myeloid leukemia or multiple myeloma
The TTI-622-01 (C4971001) study is testing an investigational study medicine for people with acute myeloid leukemia or multiple myeloma. The study medicine works by blocking signals in your immune system, allowing it to attack and kill the cancer cells.
Who may participate
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
Frequently asked questions
What is Acute Myeloid Leukemia?
Acute myeloid leukemia (AML) is a blood cancer that starts in the bone marrow and spreads to the blood. In AML, the body overproduces immature blood cells that, unable to function properly, end up crowding out healthy blood cells.
What is Multiple Myeloma?
Multiple myeloma is a type of blood cancer that forms in bone marrow. Healthy bone marrow produces plasma cells, which make antibodies to fight infection. But in multiple myeloma, plasma cells become cancerous. These cancer cells can crowd out normal blood cells, forming tumors and leaving a person vulnerable to infection.
How does the study medicine work?
The study medicine works by helping your immune system to target and kill cancer cells.